Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Physiologic Investigation of the Renin Angiotensin Aldosterone Axis in HIV

This study has been completed.
Information provided by (Responsible Party):
Steven K. Grinspoon, MD, Massachusetts General Hospital Identifier:
First received: July 27, 2011
Last updated: August 3, 2016
Last verified: August 2016

July 27, 2011
August 3, 2016
January 2012
March 2015   (final data collection date for primary outcome measure)
24-hour urine aldosterone to creatinine ratio [ Time Frame: baseline ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01407237 on Archive Site
  • Plasma Renin Activity [ Time Frame: baseline ] [ Designated as safety issue: No ]
  • Aldosterone response to Angiotensin II Infusion [ Time Frame: baseline ] [ Designated as safety issue: No ]
  • Flow mediated dilation [ Time Frame: baseline ] [ Designated as safety issue: No ]
  • Intramyocellular Lipid [ Time Frame: baseline ] [ Designated as safety issue: No ]
  • Hepatic fat [ Time Frame: baseline ] [ Designated as safety issue: No ]
  • Insulin stimulated glucose uptake [ Time Frame: baseline ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
Physiologic Investigation of the Renin Angiotensin Aldosterone Axis in HIV
Physiologic Investigation of the Renin Angiotensin Aldosterone Axis in HIV
The purpose of this study is to see if individuals with HIV-infection, particularly those with increased belly fat, have abnormalities in the renin angiotensin aldosterone axis. Renin, angiotensin, and aldosterone are hormones that regulate salt and water balance in the body, and they may also have effects on sugar metabolism and cardiovascular health. There is some evidence that individuals with HIV-associated abdominal fat accumulation may have increased aldosterone, which may contribute to abnormalities in sugar metabolism and increased cardiovascular disease seen in HIV. The purpose of this study is the measure renin, angiotensin, and aldosterone activity, as well as other hormonal axes, in people with and without HIV infection, and with and without increased belly fat. The investigators hypothesize that aldosterone will be increased in HIV-infected individuals compared to those without HIV-infection, and that aldosterone will be further increased in HIV-infected individuals with increased abdominal fat compared to those without abdominal fat accumulation.
Not Provided
Observational Model: Cohort
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Non-Probability Sample
50 HIV-infected and 50 non-HIV-infected male and female volunteers, ages 18-65 years old.
Drug: Angiotensin II Infusion
Angiotensin II (Bachem) will be infused at 0.3 ng/kg/min for 30 minutes, then 1.0 ng/kg/min for 30 minutes, then 3.0 ng/kg/min for 30 minutes; at baseline and at each infusion concentration, serum aldosterone will be measured. BP and heart rate will be monitored at baseline and every 2 minutes during the infusion.
  • HIV-infected Individuals
    Intervention: Drug: Angiotensin II Infusion
  • non-HIV-infected Individuals
    Intervention: Drug: Angiotensin II Infusion
Srinivasa S, Fitch KV, Wong K, Torriani M, Mayhew C, Stanley T, Lo J, Adler GK, Grinspoon SK. RAAS Activation Is Associated With Visceral Adiposity and Insulin Resistance Among HIV-infected Patients. J Clin Endocrinol Metab. 2015 Aug;100(8):2873-82. doi: 10.1210/jc.2015-1461.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Not Provided
March 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Stable use of antiretroviral therapy for at least 3 months (HIV group)
  2. Age ≥ 18 and ≤ 65 years of age

Exclusion Criteria:

  1. Antihypertensive use, including angiotensin converting enzyme inhibitors or angiotensin II receptor blocker use, diuretics, beta-blockers, calcium-channel blockers, potassium supplements, and spironolactone; and/or blood pressure (BP) >140/90 at screen
  2. Current or recent steroid use within last 2 months.
  3. Known diabetes and/or use of antidiabetic medications
  4. Creatinine > 1.5 mg/dL
  5. Potassium (K) > 5.5 mEq/L
  6. Hemoglobin (Hgb) < 11.0 mg/dL
  7. Alanine aminotransferase (ALT) > 2.5 x upper limit of normal (ULN)
  8. Thyroid disease/abnormal thyroid stimulating hormone (TSH)
  9. Significant electrocardiographic abnormalities at screen such as heart block or ischemia
  10. History of congestive heart failure, stroke, myocardial infarction, or known coronary artery disease (CAD)
  11. For women: Pregnant or actively seeking pregnancy, or breastfeeding
  12. Estrogen, progestational derivative, growth hormone (GH), growth hormone releasing hormone (GHRH) or ketoconazole use within 3 months.
  13. Current viral, bacterial or other infections (excluding HIV)
  14. Current cigarette smoker/use of nicotine (patch/gum) or current active substance abuse
18 Years to 65 Years   (Adult)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Not Provided
Steven K. Grinspoon, MD, Massachusetts General Hospital
Massachusetts General Hospital
Not Provided
Not Provided
Massachusetts General Hospital
August 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP